These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 27727274)

  • 1. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A; Cobelens FG; Cohen T
    PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
    Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.
    Charan J; Reljic T; Kumar A
    Indian J Pharmacol; 2016; 48(2):186-91. PubMed ID: 27127322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
    Borisov SE; D'Ambrosio L; Centis R; Tiberi S; Dheda K; Alffenaar JW; Amale R; Belilowski E; Bruchfeld J; Canneto B; Denholm J; Duarte R; Esmail A; Filippov A; Davies Forsman L; Gaga M; Ganatra S; Igorevna GA; Lazaro Mastrapa B; Manfrin V; Manga S; Maryandyshev A; Massard G; González Montaner P; Mullerpattan J; Palmero DJ; Pontarelli A; Papavasileiou A; Pontali E; Romero Leyet R; Spanevello A; Udwadia ZF; Viggiani P; Visca D; Sotgiu G; Migliori GB
    J Infect; 2019 Jan; 78(1):35-39. PubMed ID: 30096332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.